Brokers Issue Forecasts for BrainsWay Ltd.’s FY2024 Earnings (NASDAQ:BWAY)

BrainsWay Ltd. (NASDAQ:BWAY) – Stock analysts at Northland Capmk lifted their FY2024 earnings per share estimates for shares of BrainsWay in a research report issued to clients and investors on Thursday, October 3rd. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings per share of $0.05 for the year, up from their previous estimate of $0.04. The consensus estimate for BrainsWay’s current full-year earnings is $0.06 per share. Northland Capmk also issued estimates for BrainsWay’s Q4 2024 earnings at $0.01 EPS, Q1 2025 earnings at $0.01 EPS, Q2 2025 earnings at $0.02 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.02 EPS and FY2025 earnings at $0.07 EPS.

BrainsWay (NASDAQ:BWAY) last posted its earnings results on Tuesday, August 6th. The company reported $0.04 earnings per share for the quarter. The firm had revenue of $10.01 million during the quarter, compared to analysts’ expectations of $9.40 million. BrainsWay had a return on equity of 1.45% and a net margin of 1.67%. During the same quarter in the previous year, the business earned ($0.05) earnings per share.

Several other research firms have also recently weighed in on BWAY. Northland Securities boosted their target price on BrainsWay from $11.00 to $12.50 and gave the stock an “outperform” rating in a research note on Thursday. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of BrainsWay in a research note on Monday, September 16th.

BrainsWay Stock Down 1.0 %

BWAY stock opened at $9.50 on Friday. The business has a 50 day moving average price of $7.83 and a 200 day moving average price of $6.54. The stock has a market cap of $158.32 million, a price-to-earnings ratio of -105.56 and a beta of 1.26. BrainsWay has a fifty-two week low of $3.09 and a fifty-two week high of $9.72.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Tucker Asset Management LLC increased its position in BrainsWay by 1,686.9% during the fourth quarter. Tucker Asset Management LLC now owns 5,450 shares of the company’s stock worth $35,000 after buying an additional 5,145 shares during the period. Quadrature Capital Ltd acquired a new position in shares of BrainsWay in the fourth quarter valued at approximately $70,000. Virtu Financial LLC acquired a new position in shares of BrainsWay in the first quarter valued at approximately $60,000. Rhumbline Advisers increased its holdings in shares of BrainsWay by 10.3% in the second quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock valued at $110,000 after purchasing an additional 1,695 shares during the period. Finally, Perritt Capital Management Inc acquired a new position in shares of BrainsWay in the second quarter valued at approximately $121,000. Institutional investors and hedge funds own 30.11% of the company’s stock.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.